GenomeDx Biosciences Corp., which markets a genomic test (Decipher®) intended to assess the aggressiveness of prostate cancer, has agreed to pay $1.99 million to the U.S. Department of Justice to resolve allegations that it violated the False Claims Act (31 U.S.C. §§ 3729 et seq.)(“FCA”) by submitting claims to Medicare for tests conducted to evaluate treatment
Latest Post
More Posts
Genetic Testing Company Agrees to Pay $1.99 Million to Resolve Allegations that it Violated the False Claims Act By Billing for Tests Not Covered Under Local Coverage Determinations
Sales and Marketing Compliance: New Federal Anti-Kickback Law May Alter How Clinical Laboratories Compensate Sales Personnel
Hospitals Need to Be Aware of CMS Changes to PAMA
Hospitals Need to Be Aware of CMS Changes to PAMA
The SUPPORT for Patients and Communities Act: Expanding Medicare Coverage of Telehealth Services to Combat the Opioid Crisis
The SUPPORT for Patients and Communities Act: Expanding Medicare Coverage of Telehealth Services to Combat the Opioid Crisis
Court Finds ACLA Claims Precluded, CMS PAMA Rules Stand
Court Finds ACLA Claims Precluded, CMS PAMA Rules Stand
Will Federal Special Registration Exception Preempt More Stringent State Rules on Remote Prescribing of Controlled Substances?
Subscribe: Subscribe via RSS
Blogs
Firm/Org